Sleeping Sickness

Authored by
mohammad looti

October 6, 2025

Sleeping Sickness

Primary Disciplinary Field(s): Parasitology, Tropical Medicine, Public Health

1. Core Definition

Sleeping sickness, officially known as **Human African Trypanosomiasis (HAT)**, is a debilitating and often fatal parasitic disease endemic to sub-Saharan Africa. It is caused by flagellate protozoan parasites of the genus *Trypanosoma brucei*, transmitted to humans through the bite of infected tsetse flies (genus *Glossina*). The disease manifests in two distinct forms, differentiated by the infecting subspecies of the parasite and their geographical distribution: *Trypanosoma brucei gambiense* (T.b.g.), responsible for the chronic West African form, and *Trypanosoma brucei rhodesiense* (T.b.r.), causing the acute East African form. HAT is characterized by an initial haemolymphatic stage, involving fever, headaches, joint pains, and anaemia, followed by a neurological stage marked by disturbances of the central nervous system, including confusion, sensory disturbances, poor coordination, and profound disruptions to the sleep-wake cycle, ultimately leading to coma and death if left untreated.

Historically, sleeping sickness has been a significant public health challenge, responsible for widespread epidemics and high mortality rates, profoundly impacting the social and economic development of affected regions. Despite considerable progress in control and elimination efforts in recent decades, primarily due to increased surveillance, improved diagnostics, and more accessible treatments, HAT remains a neglected tropical disease. Its complex epidemiology, involving human, animal, and insect hosts, alongside the challenges of diagnosing and treating individuals in remote, resource-limited settings, necessitates sustained international collaboration and innovative approaches to achieve its ultimate eradication.

2. Etymology and Historical Development

The term "sleeping sickness" is derived from one of the most striking symptoms of the advanced neurological stage of the disease: severe disruption of the sleep-wake cycle, leading to irresistible daytime drowsiness and nocturnal insomnia. Historical accounts of a debilitating disease with these characteristics date back centuries in Africa. Early descriptions from explorers and missionaries in the 17th and 18th centuries documented a mysterious illness causing profound lethargy, emaciation, and eventual death. However, it was not until the late 19th and early 20th centuries that the scientific basis of HAT began to be unravelled, coinciding with the era of major tropical disease discoveries.

The causative agent, *Trypanosoma brucei*, was first identified in animal blood by Sir David Bruce in 1895, though its connection to human disease was initially unclear. The definitive link between trypanosomes and human sleeping sickness was established by Robert Koch and Aldo Castellani in the early 1900s, who observed the parasites in the cerebrospinal fluid of patients. Concurrently, the role of the tsetse fly as the vector for transmission was elucidated by Aldo Castellani, leading to a profound understanding of the disease's epidemiology. Major epidemics erupted in Uganda, Congo, and other parts of Africa between 1896 and 1906, causing hundreds of thousands of deaths and catalyzing significant international research and control efforts. These early efforts focused on vector control, population resettlement, and the development of the first effective, albeit highly toxic, arsenical drugs like Atoxyl. The historical fight against sleeping sickness highlights a complex interplay of scientific discovery, colonial-era public health interventions, and the enduring challenge of controlling a vector-borne zoonotic disease.

3. Key Characteristics

Human African Trypanosomiasis is characterized by a multifaceted pathology that progresses through distinct stages, influenced by the specific subspecies of the parasite involved and the host's immune response. Understanding these characteristics is crucial for effective diagnosis, treatment, and control strategies. The disease's impact extends beyond immediate illness, affecting communities through its debilitating nature and the socio-economic burdens it imposes.

3.1 Causative Agent and Vector

Sleeping sickness is caused by two subspecies of the protozoan parasite *Trypanosoma brucei*: *Trypanosoma brucei gambiense* (T.b.g.) and *Trypanosoma brucei rhodesiense* (T.b.r.). T.b.g. is responsible for over 98% of reported cases, primarily found in West and Central Africa, causing a chronic form of the disease that can last for years before symptoms become severe. T.b.r., found in East and Southern Africa, causes an acute form that progresses rapidly, often leading to death within weeks or months. The primary vector for both forms is the **tsetse fly** (genus *Glossina*), which inhabits specific ecological niches in sub-Saharan Africa. The tsetse fly transmits the parasite through its bite, acquiring trypanosomes from infected humans or animals (especially wild and domestic ungulates for T.b.r. and occasionally pigs for T.b.g.).

The life cycle of the parasite is complex, involving both the tsetse fly and a mammalian host. When an infected tsetse fly bites a human, metacyclic trypomastigotes are injected into the skin. These parasites then transform into bloodstream trypomastigotes, multiplying in the blood, lymph, and interstitial spaces. In the tsetse fly, ingested bloodstream trypomastigotes transform into procyclic trypomastigotes in the midgut, multiply, and then migrate to the salivary glands, where they transform into epimastigotes and finally into infective metacyclic trypomastigotes. This intricate cycle underscores the challenges in controlling transmission, as interventions must target either the human reservoir, animal reservoirs, or the insect vector itself.

3.2 Clinical Manifestations

The clinical course of sleeping sickness is divided into two stages. The **first stage**, or haemolymphatic stage, occurs when trypanosomes are circulating in the blood and lymph. Symptoms are non-specific and can include fever, severe headaches, joint pains, malaise, and itching. A characteristic sign of T.b.g. infection is the presence of a chancre, a painful sore at the site of the tsetse fly bite, which typically appears within days of infection and usually resolves spontaneously. Enlarged lymph nodes, particularly in the posterior cervical region (Winterbottom's sign), are also common in T.b.g. infections. This stage can last for months or even years in T.b.g. cases, making early diagnosis challenging due to the insidious onset and generalized symptoms, often mimicking other febrile illnesses. In T.b.r. infections, this stage is much shorter and more severe, rapidly progressing to the second stage.

The **second stage**, or neurological stage, begins when the parasites cross the blood-brain barrier and invade the central nervous system (CNS). This invasion leads to a range of severe neurological and psychiatric symptoms. The most prominent symptom, giving the disease its name, is the disruption of the sleep-wake cycle, characterized by irresistible daytime sleepiness (somnolence) and nocturnal insomnia. Other neurological signs include confusion, tremors, motor weakness, gait disturbances, speech difficulties, sensory abnormalities, and severe headaches. Psychiatric manifestations can include personality changes, irritability, aggressive behaviour, and delusions. Without treatment, the neurological damage progresses, leading to profound lethargy, coma, and ultimately death from complications such as malnutrition, secondary infections, or organ failure.

3.3 Diagnosis

Accurate and timely diagnosis of sleeping sickness is critical for effective treatment and to prevent progression to the fatal neurological stage. The diagnostic process typically involves a combination of screening, confirmatory tests, and staging. Given that HAT primarily affects remote communities with limited access to sophisticated medical facilities, robust and simple diagnostic tools are essential.

Screening: For T.b.g., mass screening of populations at risk is performed using the **Card Agglutination Test for Trypanosomiasis (CATT)**, which detects antibodies against the parasite in blood. While highly sensitive, CATT can produce false positives, necessitating further confirmatory tests. For T.b.r., there is no equivalent serological screening test; diagnosis often relies on clinical suspicion and direct parasite detection.

Parasite Detection: Definitive diagnosis requires the direct visualization of trypanosomes. This can be achieved by examining various body fluids:

Blood: Microscopic examination of thick and thin blood smears, or through concentration techniques like the microhaematocrit centrifugation technique (MHCT) or anion-exchange mini-column technique (mAECT).
Lymph node aspirate: Examination of fluid aspirated from enlarged lymph nodes (especially for T.b.g.).
Cerebrospinal fluid (CSF): Obtained via lumbar puncture, CSF examination is crucial for staging the disease. The presence of trypanosomes or an elevated white blood cell count (particularly lymphocytes and plasma cells) in the CSF indicates CNS involvement and marks the neurological stage.

Staging: Once an infection is confirmed, it is essential to determine whether the disease is in the first (haemolymphatic) or second (neurological) stage, as treatment protocols differ significantly. This is primarily done through CSF analysis. Identifying trypanosomes in the CSF or a CSF white blood cell count exceeding 5 cells/µL typically indicates CNS involvement.

Challenges in diagnosis include the fluctuating parasitaemia, especially in T.b.g., and the need for skilled personnel and equipment in often remote settings. Newer molecular diagnostic tools, such as PCR, are being developed but are not yet widely available for routine field use.

3.4 Treatment and Management

Treatment for sleeping sickness depends critically on the stage of the disease, as drugs effective in the first stage may not cross the blood-brain barrier sufficiently to treat the neurological stage. Historically, treatments were highly toxic, but significant advances have led to safer and more effective therapeutic options, contributing to the decline in new cases.

First Stage (Haemolymphatic):

Pentamidine: This drug is effective against T.b.g. in the first stage. It is administered intramuscularly and is generally well-tolerated, though side effects can include hypotension and renal impairment.
Suramin: Used for T.b.r. in the first stage. Administered intravenously, Suramin is effective but requires careful monitoring due to potential kidney damage and allergic reactions.

Second Stage (Neurological):

Melarsoprol: An arsenic-derived compound, Melarsoprol was historically the only treatment for the neurological stage of both T.b.g. and T.b.r. It is highly effective but associated with severe side effects, including reactive encephalopathy (leading to death in 3-10% of treated patients). Due to its toxicity, its use has significantly declined, particularly for T.b.g.
Eflornithine: Introduced in the 1990s, Eflornithine is much safer than Melarsoprol and effective

against T.b.g. in the second stage. It requires intravenous administration multiple times a day for an extended period, which can be challenging in remote settings.
Nifurtimox-Eflornithine Combination Therapy (NECT): Recommended by the World Health Organization (WHO), NECT combines Nifurtimox (an oral drug) with Eflornithine. This combination is highly effective against T.b.g. in the second stage, has improved efficacy, and reduces the duration and complexity of Eflornithine monotherapy.
Fexinidazole: A significant breakthrough, Fexinidazole is an oral drug approved in 2018 for the treatment of T.b.g. in both the first and early second stages (without severe neurological involvement). Its oral administration simplifies treatment considerably, making it a game-changer for control programs.
Acoziborole: A new single-dose oral drug currently in advanced clinical trials, Acoziborole promises to further revolutionize HAT treatment by simplifying administration even more, potentially allowing for "test-and-treat" strategies in the field.

Post-treatment follow-up, involving regular clinical examinations and CSF analysis, is essential for several years to detect potential relapses. Management also includes supportive care for complications arising from the disease or its treatment.

3.5 Prevention and Control

Prevention and control of sleeping sickness rely on a multi-pronged approach that addresses both the human reservoir and the tsetse fly vector. Sustained efforts by national control programs, supported by international partners like the WHO, have led to a dramatic reduction in cases, bringing the disease closer to elimination.

Active Surveillance and Case Finding: This involves systematic screening of at-risk populations in endemic areas using mobile teams. Early detection and treatment of cases prevent further transmission within the community.

Vector Control: Reducing tsetse fly populations is a key strategy. Methods include:

Insecticide-treated targets and traps: Odour-baited traps and targets impregnated with insecticides attract and kill tsetse flies. These are particularly effective and environmentally friendly.
Ground spraying: Targeted application of insecticides in tsetse habitats.
Aerial spraying: Used in some large-scale control campaigns.
Sterile Insect Technique (SIT): Involves releasing sterile male tsetse flies to reduce reproduction in natural populations, proven effective in specific regions.

Animal Reservoir Control (for T.b.r.): As T.b.r. is primarily a zoonotic disease, controlling the infection in domestic animals (cattle) can help reduce transmission to humans. This may involve trypanocidal treatment of livestock.

Community Engagement and Education: Raising awareness about the disease, its transmission, symptoms, and the importance of seeking early diagnosis and treatment is vital for sustainable control.

Research and Development: Ongoing research into new, simpler diagnostic tools, more effective and less toxic oral drugs, and novel vector control methods is crucial to overcome remaining challenges and achieve elimination goals.

4. Significance and Impact

The significance of sleeping sickness lies not only in its devastating clinical course but also in its profound socio-economic impact on affected communities in sub-Saharan Africa. Historically, large epidemics have depopulated entire villages, disrupted agricultural activities, and led to widespread poverty and famine. The disease disproportionately affects rural populations whose livelihoods depend on agriculture, fishing, and hunting, as these activities often bring them into close contact with tsetse fly habitats. The chronic nature of T.b.g. infection means that individuals can be ill for extended periods, unable to work or care for their families, further entrenching poverty.

Beyond direct mortality and morbidity, HAT places a heavy burden on fragile health systems in endemic countries. The need for specialized diagnostic procedures (e.g., lumbar punctures for CSF analysis) and complex treatment regimens (e.g., intravenous drug administration over days or weeks) strains limited resources and skilled personnel. The disease also carries a significant stigma, leading to social isolation and delayed presentation for treatment. The success in reducing new cases over the past two decades demonstrates the feasibility of controlling this disease, offering hope for its elimination as a public health problem. This success is a testament to sustained efforts in surveillance, control programs, and the development of new treatments, highlighting the importance of global health initiatives in combating neglected tropical diseases.

5. Debates and Criticisms

Despite significant progress in combating sleeping sickness, several debates and criticisms persist regarding current strategies and future challenges. One key area of concern is the sustainability of control programs, particularly as case numbers decline. There is a risk of complacency and reduced funding, which could lead to a resurgence of the disease, as seen historically. Maintaining surveillance and vector control in vast, often remote areas, especially for the animal reservoir of T.b.r., remains a formidable logistical and financial challenge.

Another debate centers on diagnostic limitations. While CATT is effective for T.b.g. screening, its reliance on antibody detection means it cannot distinguish between past and active infections and requires confirmation. For T.b.r., the lack of a reliable field-friendly serological test means diagnosis often relies on less sensitive direct parasite detection methods. The development and deployment of truly point-of-care, highly sensitive, and specific diagnostics for both forms of HAT are critical. Furthermore, while new oral drugs like Fexinidazole and Acoziborole represent major advances, ensuring their equitable access and preventing the emergence of drug resistance will require careful stewardship. The ultimate goal of elimination, rather than just control, also raises questions about the necessary intensity and duration of interventions, as well as the need for robust post-elimination surveillance mechanisms to prevent re-establishment of transmission.

Further Reading

World Health Organization (WHO) - Human African Trypanosomiasis (sleeping sickness)

Wikipedia - Sleeping sickness

Centers for Disease Control and Prevention (CDC) - African Trypanosomiasis (Sleeping Sickness)

Doctors Without Borders (MSF) - Sleeping Sickness: Progress and Challenges